On the other hand, glibenclamide, a potent sulfonylurea used orally in small doses in the management of type 2 DM, causes stimulation of pancreatic beta cells leading to the release of insulin and causes hypoglycemia (Candasamy et al., 2014). Here, INS is linked to Hypoglycemia.